Literature DB >> 15726249

Volume cerebral blood flow reduction in pre-clinical stage of Alzheimer disease: evidence from an ultrasonographic study.

Nabil Maalikjy Akkawi1, B Borroni, C Agosti, M Magoni, M Broli, A Pezzini, A Padovani.   

Abstract

The association of decreased cerebral blood flow with the development of Alzheimer's disease (AD) has been a recent target of interest. By using neuroimaging techniques, growing attention has been devoted to the identification of preclinical AD. In this study, color duplex sonography of cervical arteries was used to measure mean cerebral blood flow (CBF) on 55 amnestic Mild Cognitive Impairment (MCI) patients. Two years after enrollment, excluding patients who progressed to dementia other than AD, two subgroups were identified, patients who developed AD (MCI converters) and patients with preserved cognitive and functional level (MCI non-converters). Examining the mean difference of CBF measured at baseline in the two subgroups obtained, a significant difference was noticed (MCI converters 539.3 +/- 114.3 vs MCI non converters 636.0 +/- 143.9, p < 0.05). MCI patients with CBF higher than median value (558 ml/min) had lower risk of developing AD (specificity 72.2%, sensitivity 68.4%) within a two year follow-up. Ultrasonography of the cervical arteries is a simple, non invasive and widespread technique useful in detecting CBF decline during the MCI stage, thus identifying patients who later will convert to AD.

Entities:  

Mesh:

Year:  2005        PMID: 15726249     DOI: 10.1007/s00415-005-0689-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

1.  Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

Authors:  M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment.

Authors:  E Arnáiz; V Jelic; O Almkvist; L O Wahlund; B Winblad; S Valind; A Nordberg
Journal:  Neuroreport       Date:  2001-03-26       Impact factor: 1.837

3.  Color duplex measurement of cerebral blood flow volume: intra- and interobserver reproducibility and habituation to serial measurements in normal subjects.

Authors:  M Schöning; P Scheel
Journal:  J Cereb Blood Flow Metab       Date:  1996-05       Impact factor: 6.200

4.  Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging.

Authors:  C C Meltzer; J K Zubieta; J Brandt; L E Tune; H S Mayberg; J J Frost
Journal:  Neurology       Date:  1996-08       Impact factor: 9.910

Review 5.  Critical threshold cerebral hypoperfusion causes Alzheimer's disease?

Authors:  J C de la Torre
Journal:  Acta Neuropathol       Date:  1999-07       Impact factor: 17.088

Review 6.  Alzheimer disease as a vascular disorder: nosological evidence.

Authors:  J C de la Torre
Journal:  Stroke       Date:  2002-04       Impact factor: 7.914

7.  Relevance of functional neuroimaging in the progression of mild cognitive impairment.

Authors:  José A Cabranes; Ramón De Juan; Marta Encinas; Alberto Marcos; Pedro Gil; Cristina Fernández; Carmen De Ugarte; Ana Barabash
Journal:  Neurol Res       Date:  2004-07       Impact factor: 2.448

8.  A study of regional cerebral blood flow and cognitive performance in Alzheimer's disease.

Authors:  J T O'Brien; S Eagger; G M Syed; B J Sahakian; R Levy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

9.  Estimation of cerebral blood flow through color duplex sonography of the carotid and vertebral arteries in healthy adults.

Authors:  M Schöning; J Walter; P Scheel
Journal:  Stroke       Date:  1994-01       Impact factor: 7.914

10.  Differentiation of multi-infarct and Alzheimer dementia by intracranial hemodynamic parameters.

Authors:  F Ries; R Horn; J Hillekamp; C Honisch; M König; L Solymosi
Journal:  Stroke       Date:  1993-02       Impact factor: 7.914

View more
  12 in total

1.  Free radical scavengers vitamins A, C, and E plus magnesium reduce noise trauma.

Authors:  Colleen G Le Prell; Larry F Hughes; Josef M Miller
Journal:  Free Radic Biol Med       Date:  2007-02-20       Impact factor: 7.376

2.  Hypertension is associated with cognitive decline in elderly people at high risk for dementia.

Authors:  Michael Wysocki; Xiaodong Luo; James Schmeidler; Karen Dahlman; Gerson T Lesser; Hillel Grossman; Vahram Haroutunian; Michal Schnaider Beeri
Journal:  Am J Geriatr Psychiatry       Date:  2012-02       Impact factor: 4.105

Review 3.  Noncoding RNAs in Alzheimer's disease.

Authors:  M Laura Idda; Rachel Munk; Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-01-12       Impact factor: 9.957

Review 4.  The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer's Disease.

Authors:  Chelsea C Hays; Zvinka Z Zlatar; Christina E Wierenga
Journal:  Cell Mol Neurobiol       Date:  2016-02-22       Impact factor: 5.046

Review 5.  Cardiac output as a potential risk factor for abnormal brain aging.

Authors:  Angela L Jefferson
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 6.  Linking vascular disorders and Alzheimer's disease: potential involvement of BACE1.

Authors:  Sarah L Cole; Robert Vassar
Journal:  Neurobiol Aging       Date:  2008-03-04       Impact factor: 4.673

7.  Global brain hypoperfusion and oxygenation in amnestic mild cognitive impairment.

Authors:  Jie Liu; Yong-Sheng Zhu; Muhammad Ayaz Khan; Estee Brunk; Kristin Martin-Cook; Myron F Weiner; C Munro Cullum; Hanzhang Lu; Benjamin D Levine; Ramon Diaz-Arrastia; Rong Zhang
Journal:  Alzheimers Dement       Date:  2013-07-18       Impact factor: 21.566

8.  The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition.

Authors:  Ihab Hajjar; Meaghan Hart; William Milberg; Vera Novak; Lewis Lipsitz
Journal:  BMC Geriatr       Date:  2009-11-18       Impact factor: 3.921

9.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

10.  The Alzheimer's disease beta-secretase enzyme, BACE1.

Authors:  Sarah L Cole; Robert Vassar
Journal:  Mol Neurodegener       Date:  2007-11-15       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.